botensilimab,balstilimab
agenus
lba 0-9 botensilimab + balstilimab in 41 mss heavily pretreated mcrc pts, 24% orr, 73% dcr, however 42% orr in pts without liver mets! #wcgic2022 #esdo 
Doctor of Medicine, resident doctor, GI cancers @ National Cancer Institute in Bratislava, Slovakia. PhD candidate(3rd year) Faculty of Medicine @ComeniusUni